BRF2 and adenocarcinoma: Univariate analysis demonstrated that the overall 5-year survival rate of patients with BRF2 protein high expression was significantly lower than that of the remaining patients among N1, T1-2, and adenocarcinoma (P = 0.008, P = 0.002, and P = 0.015, resp.; Figure 3).